---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-055083"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-12-03T23:59:59+00:00"
generated_at: "2026-05-16T15:04:56.388101+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vistagen appoints Nick Tressler as CFO effective Dec 1, 2025

## Summary
- Nick Tressler named CFO & Treasurer, effective Dec 1, 2025; succeeds Shawn Singh as interim PFO.
- Starting annual base salary of $450,000; signing bonus of $50,000; target cash bonus of 45% of base.
- Granted inducement option for 150,000 shares at $4.43 per share; vests over 4 years with 1-yr cliff.
- Tressler brings 20+ years life sciences finance experience; most recently CFO at DYNEX Technologies.
- Shawn Singh will no longer serve as interim principal financial and accounting officer.

## SEC filing metadata
- accession: 0001628280-25-055083
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-12-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828025055083/0001628280-25-055083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828025055083/vtgn-20251128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-055083
- JSON: https://secwatch.observer/filing/0001628280-25-055083.json
- Plain text: https://secwatch.observer/filing/0001628280-25-055083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.